Kamal A, Elmoety AAA, Rostom YA, Shater MS, Lashen SA. Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study. Clin Exp Hepatol 2021;7:66-73. [PMID: 34027117 DOI: 10.5114/ceh.2021.104397][Reference Citation Analysis]
2
Armandi A, Caviglia GP, Saracco GM, De Marco L, Fagoonee S, Pellicano R. Seronegative occult hepatitis C virus infection: what is its clinical relevance? Minerva Biotecnol 2020;32. [DOI: 10.23736/s1120-4826.20.02637-3][Reference Citation Analysis]
3
Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022; 10(6): 1764-1774 [DOI: 10.12998/wjcc.v10.i6.1764][Reference Citation Analysis]